The Life Sciences landscape is changing. Government funding is on the decline; the general healthcare landscape is changing; patient pressure is increasing, and regulation is becoming stricter. The business climate is challenging: funding is scarce and Big Pharma is crucial for exits, particularly until the IPO market improves.
'Big Pharma' continues to be confronted with the 'patent cliff', drying-up pipelines and increasing convergence in the market. Due to government pressure, competition from generics and biosimilars is on the march. Start-ups and 'later stage' companies are finding it more difficult to attract funding from traditional venture capital funds, who are themselves struggling to attract investors. Alternative funding sources are increasingly explored. The biotech companies continue to be innovative and much potential is based on excellent fundamental science and increasingly experienced biotech management. New strategic joint ventures are arising with Big Pharma, while other companies are disappearing from the market. The ecosystem between biotech, Big Pharma and investors is becoming more tight-knit. Government and insurers are increasingly looking to innovations that will fundamentally lower the cost of healthcare. All of this is taking place in an extremely competitive market under the pressure of rapidly changing economic cycles.
Advice based on in-depth knowledge
NautaDutilh’s services are geared to respond effectively to this changing scenery. Our advice and propositions are built around product and business cycles: from founding a company, financing rounds and investment arrangements, licencing agreements, joint venture agreements, IPOs and M&As from venture companies through to acquisition by listed life sciences companies and other exits to sector-specific regulations, permits, fees, patent disputes, risk management and compliance. Our specialists in corporate law/M&A, intellectual property, tax, regulatory, banking & finance and employment law work together in a single, integrated Life Sciences team. This combination provides unrivalled legal expertise and in-depth knowledge of the market. We share this knowledge with our clients, progressively updating it, in the form of pragmatic, cost-effective, engaged advice, tailored to their specific, individual needs.
Years of experience and a strong network in the sector
Our team advises national and international clients in the pharmaceutical, biotechnology and medical devices sectors, from start-ups to market leaders. We act both behind the scenes and in court where necessary. Thanks to our extensive experience and active participation in many large professional organisations (for example, HollandBio, Bio.be and Flandersbio) we have built a powerful network and a comprehensive knowledge base of the sector. We are a co-founder of the Belgian Master Class in Biotechnology, run by the Institute of Pharmaceutical Business Administration. Our lawyers publish and speak regularly on such subjects as handling regulation, competition, IP and financing in the pharmaceutical, biotechnical and medical devices sectors.